5 March 2019 - - Canada- and US-based clinical-stage biopharmaceutical company Fusion Pharmaceuticals has appointed John J. Crowley as chief financial officer, the company said.

In this position, Crowley will lead Fusion's finance function, reporting to John Valliant, Ph.D., chief executive officer of Fusion Pharmaceuticals.

Crowley brings to Fusion over 20 years of global biotechnology financial and operational experience. Most recently, he served as executive vice president and chief financial officer at Merus, Inc., where he led the finance and investor relations functions and was instrumental in the build-out of the company's US and global operations.

Prior to joining Merus, Crowley served as corporate senior vice president, corporate controller and chief accounting officer of Charles River Laboratories, Inc.

Previously, he served as vice president, corporate controller and chief accounting officer of Ironwood Pharmaceuticals, Inc. and held senior corporate finance positions at Vertex Pharmaceuticals, Inc. and Sunovion Pharmaceuticals, Inc.

Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company located in Hamilton, Ontario, Canada and Boston, MA, focused on becoming a leader in the targeted alpha therapy field.

Fusion said it will exploit its unique expertise in linking medical isotopes to targeting molecules, via its proprietary Fast-Clear Technology Platform, to create highly effective therapeutics.

In addition to its lead program, FPI-1434, which had its first patient dosed in a Phase I trial in February 2019, Fusion is expanding its pipeline of products through a proprietary protein discovery platform, in-licensing targeting molecules, and forming new strategic partnerships.